Form 4 for VIR Vir Biotechnology, Inc.
Accepted 2026-02-26 00:00:00 ET · period of report 2026-02-24 · accession 0001628280-26-012394 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-02-26 | 2026-02-24+ | VIR | Eisner Mark | EVP, Chief Medical Off | S - Sale | $9.69 | -3,505 | 155.9K | -2% | -$34.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-25 | S | D | 1,889 | $9.82 | 154,024 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-24 | S | D | 1,616 | $9.53 | 155,913 | D | — | — |